Detection of induced resistance in short-term-tests. Adriamycin-resistant sarcoma 180

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Chemotherapy resistance is a major challenge in cancer treatment.
• Developing reliable methods to predict drug resistance is crucial for effective therapy.

Purpose of the Study:

• To investigate the development of drug resistance in sarcoma 180 (ascites) tumor cells.
• To evaluate the correlation between in vivo and in vitro drug sensitivity testing.

Main Methods:

• Sarcoma 180 (ascites) cells were subjected to prolonged treatment with adriamycin and triaziquone in NMRI mice.
• Drug resistance was assessed using both animal experiments (in vivo) and a short-term in vitro test.
• Correlation between in vivo and in vitro results was analyzed.

Main Results:

• Adriamycin treatment over 30 passages resulted in a resistant tumor cell line, detectable in both animal experiments and the short-term test.
• Treatment with triaziquone over 50 passages did not induce detectable resistance in either in vitro or in vivo tests.
• A strong correlation between in vivo and in vitro sensitivity/resistance results was observed across all experiments.

Conclusions:

• Adriamycin can induce resistance in sarcoma 180 (ascites) cells, which can be reliably predicted by in vitro testing.
• Triaziquone did not induce resistance under the tested conditions.
• The study validates the use of short-term in vitro tests for predicting in vivo drug response in cancer therapy.